EUVIMED · CrossrefZeitschrift
Journal of Cutaneous Oncology
ISSN 2837-1933 · Society of Cutaneous Oncology
Neueste Artikel
Authorship Begins Before the Byline
Neoadjuvant ICI for Resectable CSCC
Ipi/Nivo for Advanced MCC
Neoadjuvant Nivo/Rela for Resectable Melanoma
Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?
Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150
Skin Cancer Chemoprevention for Solid Organ Transplant Recipients - The Search Continues
Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?
Immunotherapy and Cardiovascular Health - A Cause for Concern?
To Screen or Not To Screen, That is the Question
Adjuvant anti-PD-1 for Merkel Cell Carcinoma: Ready for the Clinic?
A Closer Look: Evaluating Mohs Surgery's Role in the Treatment of Invasive Melanoma of the Head and Neck
Imaging Surveillance for Stage III Melanoma: Should We Be Stalkers or Casual Observers?
Perspectives on Medical Aid in Dying: A Multifaceted Ethical Discussion
Tumor-Infiltrating Lymphocyte Therapy Receives FDA Approval
Should Ipilimumab Be the New “Standard” for Refractory MCC?
Comparing First-Line Immunotherapy in Advanced Melanoma: No Clear Winner?
The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities
Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain
Evolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630
Persuaded, Not Certain: Why I Voted Yes
Neoadjuvant Intralesional Daromun in Resectable Melanoma: Interpreting the PIVOTAL Trial
EUVIMED